融券方面，润和软件1月9日融券偿还2.00万股，融券卖出5500.00股，按当日收盘价计算，卖出金额 28.78万元；融券余量21.64万股，融券余额1132.42万元，低于近一年10%分位水平，处于低位。 1月9日，润和软件涨2.07%，成交额22.98亿元。两融数据显示，当日润和软件获融资买入额3.31亿元， 融资偿还3.04亿元，融资净买入2743.15万元。截至1月9日，润和软件融资融券余额合计32.34亿元。 融资方面，润和软件当日融资买入3.31亿元。当前融资余额32.23亿元，占流通市值的7.73%，融资余额 低于近一年40%分位水平，处于较低位。 截至9月30日，润和软件股东户数23.35万，较上期增加1.43%；人均流通股3331股，较上期减少1.41%。 2025年1月-9月，润和软件实现营业收入27.19亿元，同比增长12.86%；归母净利润7857.26万元，同比减 少29.01%。 分红方面，润和软件A股上市后累计派现3.77亿元。近三年，累计派现5526.72万元。 机构持仓方面，截止2025年9月30日，润和软件十大流通股东中，易方达创业板ETF（159915）位居第 二大流通股 ...

1月9日，中科金财涨2.16%，成交额8.31亿元。两融数据显示，当日中科金财获融资买入额9947.47万 元，融资偿还1.05亿元，融资净买入-597.16万元。截至1月9日，中科金财融资融券余额合计7.19亿元。 融券方面，中科金财1月9日融券偿还0.00股，融券卖出1.60万股，按当日收盘价计算，卖出金额46.96万 元；融券余量2.44万股，融券余额71.61万元，超过近一年80%分位水平，处于高位。 资料显示，北京中科金财科技股份有限公司位于北京市海淀区小月河东畔路16号院2号楼5层501-1号房 屋，成立日期2003年12月10日，上市日期2012年2月28日，公司主营业务涉及应用软件开发、技术服务 及相关的计算机信息系统集成服务。主营业务收入构成为：数据中心综合服务50.81%，金融科技综合 服务31.66%，人工智能综合服务14.01%，其他(补充)3.52%。 融资方面，中科金财当日融资买入9947.47万元。当前融资余额7.19亿元，占流通市值的7.23%，融资余 额超过近一年70%分位水平，处于较高位。 分红方面，中科金财A股上市后累计派现6045.78万元。近三年，累计派现0.00元。 ...

证券时报 数据宝统计显示，截至1月9日，深沪北两融余额为26276.01亿元，与前一周末相比增加869.18 亿元，单周增加金额创2025年9月5日以来新高，其中融资余额26099.35亿元，一周增加857.79亿元，单 周增加金额创2025年9月5日以来新高，融券余额176.66亿元，一周增加11.39亿元。 注：本文系新闻报道，不构成投资建议 一周深沪北两融余额变动 | 日期 | 两融余额 | 两融余额环比增 | 融资余额 | 融资余额环比增 | 融券余额 | 融券余额环比增 | | --- | --- | --- | --- | --- | --- | --- | | | （亿元） | 减（亿元） | （亿元） | 减（亿元） | （亿元） | 减（亿元） | | 2026.01.09 | 26276.01 | 69.91 | 26099.35 | 67.81 | 176.66 | 2.11 | | 2026.01.08 | 26206.09 | 158.67 | 26031.55 | 159.44 | 174.55 | -0.77 | | 2026.01.07 | 26047.42 | 248.42 ...

Core Insights - Jin Di Co., Ltd. experienced a stock price increase of 1.39% on January 9, with a trading volume of 174 million yuan [1] - The company reported a financing buy-in amount of 24.10 million yuan and a net financing buy of -128,600 yuan on the same day [1] - As of January 9, the total financing and securities lending balance for Jin Di Co., Ltd. was 157 million yuan, representing 8.25% of its circulating market value [1] Financing Summary - On January 9, Jin Di Co., Ltd. had a financing buy-in of 24.10 million yuan, with a current financing balance of 157 million yuan, which is above the 90th percentile level over the past year [1] - The company had a securities lending repayment of 300 shares on January 9, with no shares sold, resulting in a securities lending balance of 28.26 million yuan, also above the 90th percentile level over the past year [1] Business Performance - As of September 30, the number of shareholders for Jin Di Co., Ltd. was 21,000, a decrease of 17.76% from the previous period, while the average circulating shares per person increased by 21.59% to 3,365 shares [2] - For the period from January to September 2025, Jin Di Co., Ltd. achieved a revenue of 1.372 billion yuan, representing a year-on-year growth of 48.58%, and a net profit attributable to shareholders of 109 million yuan, up 30.06% year-on-year [2] - The company has distributed a total of 131 million yuan in dividends since its A-share listing [2] Shareholder Composition - As of September 30, 2025, Hong Kong Central Clearing Limited was the third-largest circulating shareholder with 1.4798 million shares, an increase of 990,500 shares from the previous period [2] - Guangfa Quantitative Multi-Factor Mixed A (005225) entered the top ten circulating shareholders as the fourth-largest with 827,200 shares [2] - Hai Futong Stock Mixed (519005) exited the list of the top ten circulating shareholders [2]

机构持仓方面，截止2025年9月30日，亚玛顿十大流通股东中，金元顺安元启灵活配置混合（004685） 退出十大流通股东之列。 责任编辑：小浪快报 资料显示，常州亚玛顿股份有限公司位于江苏省常州市天宁区青龙东路616号，成立日期2006年9月11 日，上市日期2011年10月13日，公司主营业务涉及光伏玻璃镀膜材料技术和工艺技术的研发,光伏玻璃 的镀膜生产以及光伏镀膜玻璃销售。主营业务收入构成为：太阳能玻璃85.54%，电子玻璃及其他玻璃 产品10.99%，电力销售2.27%，太阳能组件0.80%，其他0.40%。 截至9月30日，亚玛顿股东户数3.15万，较上期增加25.12%；人均流通股6308股，较上期减少20.08%。 2025年1月-9月，亚玛顿实现营业收入15.80亿元，同比减少35.42%；归母净利润-5957.04万元，同比减 少123.67%。 分红方面，亚玛顿A股上市后累计派现3.19亿元。近三年，累计派现2.32亿元。 1月9日，亚玛顿跌0.22%，成交额6499.33万元。两融数据显示，当日亚玛顿获融资买入额463.61万元， 融资偿还553.56万元，融资净买入-89.95万元。截至 ...

Group 1 - On January 9, Dongcheng Pharmaceutical's stock increased by 0.55%, with a trading volume of 162 million yuan. The financing buy amount was 13.51 million yuan, while the financing repayment was 15.99 million yuan, resulting in a net financing buy of -2.49 million yuan. The total financing and securities balance reached 1.13 billion yuan [1] - The financing balance of Dongcheng Pharmaceutical is 1.13 billion yuan, accounting for 9.47% of the circulating market value, which is above the 80th percentile level over the past year, indicating a high level [1] - On the same day, the company had a securities lending repayment of 300 shares and a securities lending sell of 9,500 shares, with a selling amount of 137,800 yuan. The remaining securities lending volume was 29,600 shares, with a balance of 429,200 yuan, which is below the 30th percentile level over the past year, indicating a low level [1] Group 2 - As of September 30, the number of shareholders of Dongcheng Pharmaceutical was 24,600, an increase of 4.51% compared to the previous period. The average circulating shares per person decreased by 4.32% to 30,191 shares [2] - For the period from January to September 2025, Dongcheng Pharmaceutical achieved an operating income of 2.04 billion yuan, a year-on-year decrease of 5.52%. The net profit attributable to the parent company was 149 million yuan, a year-on-year decrease of 10.64% [2] - Since its A-share listing, Dongcheng Pharmaceutical has distributed a total of 1 billion yuan in dividends, with 293 million yuan distributed in the last three years [3]

Core Viewpoint - Zhongji Xuchuang experienced a decline of 2.06% on January 9, with a trading volume of 22.201 billion yuan, indicating a significant market activity around the stock [1] Group 1: Financing and Margin Trading - On January 9, Zhongji Xuchuang had a financing buy-in amount of 3.517 billion yuan and a financing repayment of 2.976 billion yuan, resulting in a net financing buy of 541 million yuan [1] - As of January 9, the total margin trading balance for Zhongji Xuchuang was 21.525 billion yuan, with a financing balance of 21.470 billion yuan, accounting for 3.31% of the circulating market value, which is above the 90th percentile level over the past year [1] - In terms of securities lending, Zhongji Xuchuang had a repayment of 8,000 shares and a sell-out of 5,200 shares on January 9, with a sell-out amount of approximately 3.0326 million yuan, indicating a high level of activity in the lending market [1] Group 2: Company Performance and Shareholder Information - As of September 30, Zhongji Xuchuang reported a total revenue of 25.005 billion yuan for the first nine months of 2025, representing a year-on-year growth of 44.43%, and a net profit attributable to shareholders of 7.132 billion yuan, up 90.05% year-on-year [2] - The company has distributed a total of 1.943 billion yuan in dividends since its A-share listing, with 1.512 billion yuan distributed over the past three years [2] - As of September 30, 2025, the number of shareholders for Zhongji Xuchuang increased to 132,300, with an average of 8,353 circulating shares per person, a decrease of 3.02% from the previous period [2]

资料显示，浙江晶盛机电股份有限公司位于浙江省杭州市临平区顺达路500号，成立日期2006年12月14 日，上市日期2012年5月11日，公司主营业务涉及晶体生长设备及其控制系统的研发、制造和销售。主 营业务收入构成为：设备及其服务70.48%，材料21.18%，其他8.34%。 1月9日，晶盛机电跌0.77%，成交额11.37亿元。两融数据显示，当日晶盛机电获融资买入额1.50亿元， 融资偿还1.34亿元，融资净买入1583.98万元。截至1月9日，晶盛机电融资融券余额合计13.66亿元。 融资方面，晶盛机电当日融资买入1.50亿元。当前融资余额13.62亿元，占流通市值的2.70%，融资余额 超过近一年90%分位水平，处于高位。 融券方面，晶盛机电1月9日融券偿还3100.00股，融券卖出1400.00股，按当日收盘价计算，卖出金额 5.40万元；融券余量10.28万股，融券余额396.40万元，超过近一年70%分位水平，处于较高位。 截至9月30日，晶盛机电股东户数8.68万，较上期增加25.88%；人均流通股14189股，较上期减少 20.56%。2025年1月-9月，晶盛机电实现营业收入82.73亿元 ...

Core Viewpoint - Dongwu Securities experienced a mixed performance in trading activities, with a notable decrease in net financing buy and a significant increase in net profit year-on-year despite a drop in revenue [1][2]. Financing Activities - On January 9, Dongwu Securities recorded a financing buy of 51.33 million yuan, with a net financing buy of -36.35 million yuan, indicating a higher level of financing repayment than new purchases [1]. - The total financing and securities lending balance reached 3.134 billion yuan, with the financing balance accounting for 6.81% of the circulating market value, which is above the 70th percentile of the past year [1]. - In terms of securities lending, 115,700 shares were repaid, while 56,500 shares were sold, resulting in a selling amount of 522,100 yuan, with a remaining securities lending balance of 7.1739 million yuan, also above the 60th percentile of the past year [1]. Financial Performance - For the period from January to September 2025, Dongwu Securities reported an operating income of 7.274 billion yuan, a year-on-year decrease of 13.78%, while the net profit attributable to shareholders increased by 60.23% to 2.935 billion yuan [2]. - Cumulatively, since its A-share listing, Dongwu Securities has distributed a total of 8.684 billion yuan in dividends, with 3.955 billion yuan distributed over the past three years [3]. Shareholder Information - As of September 30, 2025, the number of shareholders increased by 24.26% to 111,100, while the average circulating shares per person decreased by 19.52% to 44,738 shares [2]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited holds 160 million shares, a decrease of 158 million shares compared to the previous period, while the Guotai CSI All-Index Securities Company ETF is a new sixth-largest shareholder with 103 million shares [3].

1月9日，民生健康涨0.87%，成交额1.32亿元。两融数据显示，当日民生健康获融资买入额1412.02万 元，融资偿还1540.19万元，融资净买入-128.17万元。截至1月9日，民生健康融资融券余额合计9134.57 万元。 机构持仓方面，截止2025年9月30日，民生健康十大流通股东中，香港中央结算有限公司位居第五大流 通股东，持股101.59万股，相比上期减少69.55万股。 责任编辑：小浪快报 资料显示，杭州民生健康药业股份有限公司位于浙江省杭州市滨江区滨安路658号，成立日期2009年12 月14日，上市日期2023年9月5日，公司主营业务涉及专注于维生素与矿物质补充剂领域,维生素与矿物 质类非处方药品和保健食品研发、生产、销售。主营业务收入构成为：维生素与矿物质补充剂系列 99.69%，其他(补充)0.31%。 截至9月30日，民生健康股东户数1.97万，较上期减少8.51%；人均流通股5547股，较上期增加7.98%。 2025年1月-9月，民生健康实现营业收入6.23亿元，同比增长19.78%；归母净利润1.14亿元，同比增长 32.77%。 分红方面，民生健康A股上市后累计派现7120. ...